Dissociation between morphine-induced spinal gliosis and analgesic tolerance by ultra-low-dose α2-adrenergic and cannabinoid CB1-receptor antagonists

Behavioural Pharmacology
Patrick GrenierCatherine M Cahill

Abstract

Long-term use of opioid analgesics is limited by tolerance development and undesirable adverse effects. Paradoxically, spinal administration of ultra-low-dose (ULD) G-protein-coupled receptor antagonists attenuates analgesic tolerance. Here, we determined whether systemic ULD α2-adrenergic receptor (AR) antagonists attenuate the development of morphine tolerance, whether these effects extend to the cannabinoid (CB1) receptor system, and if behavioral effects are reflected in changes in opioid-induced spinal gliosis. Male rats were treated daily with morphine (5 mg/kg) alone or in combination with ULD α2-AR (atipamezole or efaroxan; 17 ng/kg) or CB1 (rimonabant; 5 ng/kg) antagonists; control groups received ULD injections only. Thermal tail flick latencies were assessed across 7 days, before and 30 min after the injection. On day 8, spinal cords were isolated, and changes in spinal gliosis were assessed through fluorescent immunohistochemistry. Both ULD α2-AR antagonists attenuated morphine tolerance, whereas the ULD CB1 antagonist did not. In contrast, both ULD atipamezole and ULD rimonabant attenuated morphine-induced microglial reactivity and astrogliosis in deep and superficial spinal dorsal horn. So, although paradoxical ef...Continue Reading

References

Mar 1, 1997·Progress in Neurobiology·J T Porter, K D McCarthy
Jan 8, 1999·Peptides·G A OlsonA J Kastin
Oct 26, 1999·Journal of Neuroscience Research·Y Chen, L Hertz
Mar 15, 2001·Neuroscience Research·P Song, Z Q Zhao
Nov 24, 2001·Annals of Emergency Medicine·S B Bird, E W Dickson
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kelly J PowellKhem Jhamandas
Aug 15, 2002·CNS Drug Reviews·R W Clarke, J Harris
Jan 7, 2004·Life Sciences·Diana L Cichewicz
Jun 8, 2004·Current Drug Targets. CNS and Neurological Disorders·L HertzL Peng
Aug 18, 2004·Biological Psychiatry·Paolo MannelliElisabeth J Van Bockstaele
Apr 29, 2005·Brain Research. Molecular Brain Research·Sumita ChakrabartiAlan R Gintzler
Jun 10, 2005·The Journal of Pain : Official Journal of the American Pain Society·Vishala L ChindaloreNadav Friedmann
Nov 16, 2005·Behavioural Pharmacology·Jay Paquette, Mary C Olmstead
Sep 13, 2006·Journal of Neurobiology·Hoau-Yan Wang, Lindsay H Burns
Dec 13, 2006·The Journal of Pain : Official Journal of the American Pain Society·Lynn R WebsterNadav Friedmann
Feb 20, 2007·European Journal of Pharmacology·Benjamin McNaullKhem Jhamandas
Jan 25, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ru-Yin TsaiChih-Shung Wong
Apr 17, 2008·British Journal of Pharmacology·M J Christie
May 17, 2008·Addiction Biology·Patricia RobledoRafael Maldonado
Jun 25, 2008·The Clinical Journal of Pain·Jane C Ballantyne, Naomi S Shin
Aug 8, 2008·Brain, Behavior, and Immunity·Joanna MikaBarbara Przewlocka
Apr 20, 2010·Molecular Pain·Theresa-Alexandra M MattioliCatherine M Cahill
Mar 31, 2011·Journal of Neurochemistry·Dana S HutchinsonMarie E Gibbs
May 6, 2011·Anesthesia and Analgesia·Brian MilneKhem Jhamandas
May 5, 2012·Anesthesia and Analgesia·Tuomas O LiliusEija A Kalso
Feb 24, 2016·Frontiers in Cellular Neuroscience·Alexandra Kaser-EichbergerSebastien Couillard-Despres

❮ Previous
Next ❯

Citations

Jun 24, 2020·Peptides·Richard J Bodnar
Apr 30, 2021·Cannabis and Cannabinoid Research·Patrick GrenierMary C Olmstead

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.